Emcyt (estramustine phosphate sodium) Capsules
Emcyt capsules are used as palliative treatment of patients with metastatic and/or progressive prostate cancer.
Pfizer Oncology Together offers 2 financial assistance programs for patients using Emcyt:
Pfizer Patient Assistance Program
Patients who are prescribed a Pfizer specialty medicine, such as Emcyt, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.
Pfizer Savings Program
Through this program, uninsured patients, regardless of income, will see an estimated savings of 36% to 75% on their medication costs when purchased at a participating retail pharmacy.
Erleada (apalutamide) Tablets
Erleada is an androgen receptor inhibitor used for the treatment of patients with non-metastatic castration-resistant prostate cancer. Erleada is also used for the treatment of patients with metastatic castration-sensitive prostate cancer.
Jannsen CarePath offers 3 financial assistance programs for patients who have been prescribed Erleada:
Janssen CarePath Savings Program
Eligible patients who have private insurance may pay only $0 per month for Erleada, with an annual benefit up to $15,000. The savings may apply toward copay, co-insurance, or deductible, depending on the patient’s health insurance plan.
Johnson & Johnson Patient Assistance Foundation
This program provides Erleada free of charge to patients who meet certain financial criteria and who are uninsured, underinsured, or are enrolled in Medicare Part D.
Jevtana (cabazitaxel)
Jevtana is a microtubule inhibitor used, in combination with prednisone, for the treatment of patients with hormone-refractory metastatic prostate cancer, after treatment with a docetaxel-based regimen.
Sanofi Genzyme offer 2 financial assistance programs for patients who are prescribed Jevtana:
CareASSIST Copay Program
Eligible patients who have commercial insurance may pay as little as $0 for Jevtana, up to a $25,000 benefit per year. Patients must have commercial or private insurance, including state or federal employee plans and health insurance exchanges.
CareASSIST Patient Assistance Program
Patients who are uninsured or are underinsured may be eligible to receive Jevtana at no cost. To be eligible for this program, the patient’s annual household income must not be more than $100,000, or 500% of the federal poverty level. Patients enrolled in Medicare Part B who have no supplemental insurance may also be eligible to receive Jevtana through this program.
Lynparza (olaparib) Capsules/Tablets
Lynparza is a PARP inhibitor used for treatment of patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR gene mutation, as determined by an FDA-approved test, in men whose disease progressed after enzalutamide or abiraterone therapy.
AstraZeneca offers 2 financial assistance programs for patients who have been prescribed Lynparza:
Lynparza Co-pay Savings Program
The patient’s out-of-pocket costs may vary, but this program aims for eligible patients to pay $0 per month for Lynparza, with a maximum out-of-pocket savings of $26,000 annually. This program has no income requirements, but eligible patients must have private health insurance that partially covers the medication costs for Lynparza.
AZ&Me Prescription Savings Program
This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year and must be unable to enroll in Medicare limited income subsidy.
Patients with Medicare Part B coverage should call 800-292-6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Lynparza (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.
Nubeqa (darolutamide)
Nubeqa is an androgen receptor inhibitor used for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Bayer offers 3 financial assistance programs for patients who have been prescribed Nubeqa:
Nubeqa Free Trial Program
Through this program, new patients who have been prescribed Nubeqa will receive this medication at no cost for 1 month.
Nubeqa $0 Co-Pay Program
Eligible patients who have private insurance may pay $0 copay for Nubeqa, with a maximum annual benefit of $25,000.
Bayer US Patient Assistance Foundation
This foundation provides Nubeqa free of charge to uninsured or underinsured patients who meet specific financial criteria.
Orgovyx (relugolix) Tablets
Orgovyx is an oral gonadotropin-releasing hormone receptor antagonist used for the treatment of patients with advanced prostate cancer. Orgovyx is the first androgen-deprivation therapy approved for patients with advanced prostate cancer.
Myovant Sciences offers 2 financial assistance programs for patients using Orgovyx:
Orgovyx Copay Assistance Program
Eligible patients who have private insurance may pay as little as $10 a month for their Orgovyx prescription through this program.
Myovant Patient Assistance Program
Eligible patients who are uninsured or underinsured may receive Orgovyx at no cost through this program.
Premarin (conjugated estrogens) Tablets
Premarin is a mixture of estrogens used as palliative treatment of patients with advanced androgen-dependent prostate cancer.
Pfizer Oncology Together offers 3 financial assistance programs for patients using Premarin:
Premarin Savings Card
With this savings card, patients who are not fully reimbursed for Premarin can pay as little as $30, with a savings of up to $55 per prescription fill. The card is limited to 12 offers and a maximum savings of $660 per calendar year.
Pfizer Patient Assistance Program
Patients who are prescribed a Pfizer specialty medicine, such as Premarin, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.
Free Medicine Through Health Centers and Hospitals
Uninsured patients may be eligible to receive Premarin tablets for free at select health centers and hospitals nationwide. Drug availability varies by institution and by patient’s eligibility.
Provenge (sipuleucel-T)
Provenge is an autologous cellular immunotherapy used for the treatment of patients with metastatic castrationresistant (hormone-refractory) prostate cancer.
Dendreon offers 3 financial assistance programs for patients using Provenge:
PROvide Commercial Co-pay Program
This program supports eligible, insured patients by covering any combination of cost (copays, co-insurance, or deductibles) to a maximum of $6,000 over 3 Provenge treatments.
Co-pay Assistance for Patients with Medicare
This program helps eligible patients with Medicare pay for copays, co-insurance, and deductibles.
Provenge Uninsured Patient Program
Patients who are uninsured and who have an adjusted gross income of $150,000 a year or less may be able to get Provenge at no cost through this program.
Pylarify (piflufolastat F18) Injection
Pylarify is a radioactive diagnostic agent used with a PET scan of PSMA-positive lesions in men with prostate cancer and suspected metastasis who are candidates for initial definitive therapy or in men with suspected cancer recurrence based on elevated serum PSA level.
Progenics Pharmaceuticals offers 1 financial assistance program for patients using Pylarify:
Pylarify Patient Support Program
This program can help patients streamline the use of Pylarify and assist with insurance assessment.
Rubraca (rucaparib) Tablets
Rubraca is a PARP inhibitor used for the treatment of adults with metastatic castration-resistant prostate cancer and a deleterious (germline and/or somatic) BRCA mutation, as detected by an FDA-approved test, who have received androgen receptor therapy and a taxane-based chemotherapy.
Clovis Oncology provides 3 financial assistance programs for patients who have been prescribed Rubraca:
Rubraca $0 Co-Pay Program
Patents with private insurance pay $0 copay for Rubraca through this program, with a maximum annual assistance up to $24,000.
Rubraca Connections Patient Assistance Program
Patients who are uninsured or underinsured who meet certain financial and residential eligibility requirements may qualify to receive Rubraca for free.
Rubraca Connections QuickStart Program
Eligible patients with private insurance who have insurance challenges can receive a 15-day supply of Rubraca and up to 90 days through this program.
Trelstar (triptorelin pamoate) for Injectable Suspension
Trelstar is a gonadotropin-releasing hormone agonist used as palliative treatment of advanced prostate cancer.
Allergan offers 1 financial assistance program for patients using Trelstar:
Allergan Patient Assistance Program
Patients who cannot afford the cost of Trelstar and meet other eligibility requirements may qualify for free medication. Eligible applicants will be enrolled for 12 months and a 90-day supply of medication will be immediately shipped to the physician. Medicare Part D applicants must have been denied low income subsidy and will only be enrolled until the end of the calendar year.
Xofigo (radium Ra 223 dichloride) Injection
Xofigo is an alpha particle-emitting radioactive therapeutic agent used for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.
Bayer offers 2 financial assistance programs for patients using Xofigo:
Xofigo Access Services $0 Copay
This program provides privately insured patients with a Commercial Copay Assistance ID card so that the copay for Xofigo is $0.
Xofigo Access Services Financial Assistance Program
This program provides Xofigo free of charge for eligible patients who are uninsured or are without coverage for Xofigo. Applicants must meet certain financial criteria.
Xtandi (enzalutamide) Tablets
Xtandi is an androgen receptor inhibitor used for the treatment of patients with castration-resistant prostate cancer. Xtandi is also used for the treatment of patients with metastatic castration-sensitive prostate cancer.
Astellas Pharma offers 3 financial assistance programs for patients using Xtandi:
XTANDI Patient Savings Program
This program allows eligible, privately insured patients to pay as little as $0 per prescription of Xtandi, with a benefit of up to $25,000 annually.
XTANDI Quick Start+ Program
Eligible, new patients awaiting coverage determination will be provided a free 14-day supply of Xtandi.
Astellas Patient Assistance Program
Patients who do not have prescription coverage for Xtandi may receive their medication at no cost through this program. Applicants must have an annual household income of less than $100,000.
Yonsa (abiraterone acetate) Tablets
Yonsa is a CYP17 inhibitor used, in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer.
Sun Pharma’s Yonsa Support offers 3 financial assistance programs for patients who have been prescribed Yonsa:
Yonsa Copay Program
Eligible patients who have private insurance may pay as little as $10 for their prescription of Yonsa through this program, with a maximum benefit of $5,000 per prescription, and $12,000 per year.
Yonsa Early Access Program
Patients facing a delay in medication coverage will be enrolled in this program and will receive free Yonsa for up to 30 days.
Yonsa Patient Assistance Program
For eligible patients who do not have commercial (private) insurance, this program will assist with the cost of Yonsa.
Zoladex (goserelin acetate implant)
Zoladex is a gonadotropin-releasing hormone agonist used, in combination with flutamide, for the treatment of patients with localized prostate cancer. Zoladex is also used as a palliative treatment of advanced prostate cancer.
TerSera Therapeutics offers 2 financial assistance programs for patients who have been prescribed Zoladex:
Zoladex Co-Pay Card
Eligible patients with private insurance may pay as little as $0 for their prescription of Zoladex, with a maximum benefit of $2,000 per year. Eligible, cash-paying patients whose prescriptions are not paid by any government programs will receive up to $300 off each 1-month supply of Zoladex.
Zoladex Patient Assistance Program
For eligible patients who don’t have commercial insurance, this program may provide free Zoladex for up to 1 year before renewal is required. The medicine is sent in a 90-day supply to the patient’s home or the doctor’s office.
Zytiga (abiraterone acetate)
Zytiga is a CYP17 inhibitor used, in combination with prednisone, for the treatment of patients with metastatic castration- resistant prostate cancer. Zytiga is also used, in combination with prednisone, for patients with metastatic high-risk castration-sensitive prostate cancer.
Janssen Biotech offers 3 financial assistance programs for patients using Zytiga:
Janssen CarePath Savings Program
With this card, privately insured patients will pay no more than $10 monthly for their medicine, with a $12,000 maximum benefit per calendar year.
Johnson & Johnson Patient Assistance Foundation
This program provides Zytiga free of charge for up to 12 months to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.
Janssen Compass
Janssen Compass offers free, personalized support to patients who are prescribed a cancer drug from Janssen. Connect one-on-one with your dedicated Care Navigator (an experienced oncology nurse), who can help you find financial assistance and provide educational treatment support based on what you tell us you need most.
Table. Drugs Prescribed for Prostate Cancer
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Emcyt (estramustine phosphate sodium) Capsules
- Pfizer
- Palliative treatment of metastatic and/or progressive prostate cancer
- Pfizer Patient Assistance Program
877-744-5675
Pfizer Savings Program
877-744-5675
- Erleada (apalutamide) Tablets
- Janssen Biotech
- Treatment of
non-metastatic
castration-resistant
prostate cancer
Treatment of metastatic castration-sensitive prostate cancer - Janssen CarePath Savings Program
833-375-3232
Johnson & Johnson Patient Assistance Foundation
800-652-6227
Janssen Compass
844-NAV-1234
- Jevtana (cabazitaxel)
- Sanofi Genzyme
- Treatment of hormone-refractory metastatic prostate cancer, in combination with prednisone, after a docetaxel-based regimen
- CareASSIST Copay Program
833-930-2273
CareASSIST Patient Assistance Program
833-930-2273
- Lynparza (olaparib) Capsules/Tablets
- AstraZeneca
- Treatment of patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR gene mutation, as determined by an FDA-approved test, in men whose disease progressed after enzalutamide or abiraterone therapy
- Lynparza Co-pay Savings Program
844-275-2360
AZ&Me Prescription Savings Program
800-292-6363
- Nubeqa (darolutamide)
- Bayer
- Treatment of non-metastatic castration-resistant prostate cancer
- Nubeqa Free Trial Program
833-337-3833
Nubeqa $0 Co-Pay Program
833-337-3833
Bayer US Patient Assistance Foundation
866-228-7723
- Orgovyx (relugolix) Tablets
- Myovant Sciences
- Treatment of patients with advanced prostate cancer
- Orgovyx Copay Assistance Program
833-674-6899
Myovant Patient Assistance Program
833-674-6899
- Premarin (conjugated estrogens) Tablets
- Pfizer
- Palliative treatment of advanced, androgendependent prostate cancer
- Premarin Savings Card
866-410-3700
Pfizer Patient Assistance Program
877-744-5675
Free medicine through health centers and hospitals
877-744-5675
- Provenge (sipuleucel-T)
- Dendreon
- Treatment of metastatic castration-resistant (hormone-refractory) prostate cancer
- PROvide Commercial Co-pay Program
877-336-3736
Co-pay Assistance for Patients with Medicare
877-336-3736
Provenge Uninsured Patient Program
877-336-3736
- Pylarify (Piflufolastat F18) Injection
- Progenics Pharmaceuticals
- For use with PET scan of men with PSMA-positive prostate cancer lesions and suspected metastasis who are candidates for initial definitive therapy or men with suspected recurrence based on elevated serum PSA level
- Pylarify Patient Support Program
844-339-8514
- Rubraca (rucaparib) Tablets
- Clovis Oncology
- Treatment of adults with metastatic castration-resistant prostate cancer and a deleterious (germline and/or somatic) BRCA mutation, as detected by an FDA-approved test, who have received androgen receptor therapy and a taxanebased chemotherapy
- Rubraca $0 Co-Pay Program
844-779-7707
Rubraca Connections Patient Assistance Program
844-779-7707
Rubraca Connections QuickStart Program
844-779-7707
- Trelstar (triptorelin pamoate) for Injectable Suspension
- Allergan
- Palliative treatment of advanced prostate cancer
- Allergan Patient Assistance Program
844-424-6727
- Xofigo (radium Ra 223 dichloride) Injection
- Bayer
- Treatment of castration-resistant prostate cancer
- Xofigo Access Services $0 Copay
855-696-3446
Xofigo Access Services Financial Assistance Program
855-696-3446
- Xtandi (enzalutamide) Tablets
- Astellas Pharma
- Treatment of
castration-resistant
prostate cancer
Treatment of patients with metastatic castration- sensitive prostate cancer - XTANDI Patient Savings Program
855-898-2634
XTANDI Quick Start+ Program
Astellas Patient Assistance Program
855-898-2634
- Yonsa (abiraterone acetate) Tablets
- Sun Pharma
- Treatment of metastatic castration-resistant prostate cancer, in combination with methylprednisolone
- Yonsa Copay Program
855-449-6672
Yonsa Early Access Program
855-449-6672
Astellas Patient Assistance Program
855-449-6672
- Zoladex (goserelin acetate implant)
- TerSera Therapeutics
- Treatment of localized
prostate cancer,
in combination with
flutamide
Palliative treatment of advanced prostate cancer - Zoladex Co-Pay Card
844-864-3014
Zoladex Patient Assistance Program
855-686-8725
- Zytiga (abiraterone acetate)
- Janssen Biotech
- Treatment of
metastatic castrationresistant
prostate
cancer, in combination
with prednisone
Treatment of metastatic high-risk castration-sensitive prostate cancer, in combination with prednisone - Janssen CarePath Savings Program
855-998-4421
Johnson & Johnson Patient Assistance Foundation
800-652-6227